In a report released yesterday, Ritu Baral from Cowen & Co. maintained a Buy rating on Global Blood Therapeutics (GBT), with a price target of $83. The company’s shares closed last Monday at $51.36.
According to TipRanks.com, Baral is a 5-star analyst with an average return of 21.7% and a 47.0% success rate. Baral covers the Healthcare sector, focusing on stocks such as Milestone Pharmaceuticals Inc, Madrigal Pharmaceuticals Inc, and ACADIA Pharmaceuticals Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Global Blood Therapeutics with a $97 average price target, implying a 92.7% upside from current levels. In a report issued on September 5, William Blair also maintained a Buy rating on the stock.
See today’s analyst top recommended stocks >>
The company has a one-year high of $64.94 and a one-year low of $30.15. Currently, Global Blood Therapeutics has an average volume of 974.6K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders. It also provides oral medicines for sickle cell diseases.
